APAXEN
0700.833.611 · rovalta.com · 23/09/2026
NORMAL SITUATION
APAXEN
Financial year 2023 · closed on 31/12/2023
Net result
-281,7 k €
+2.5% YoY
Gross margin
-163,2 k €
-17.2% YoY
Equity
4,8 M €
+12.4% YoY
Company — Normal situation.
Overview
What does APAXEN do?
APAXEN is a company registered in Belgium.
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0700.833.611
Legal form
Public limited company
Contributed capital
5 162 519,56 €
Latest accounts
31/12/2023
Joint committees (1)
- 207
Signals
Solid equityGood liquidityHealthy social debts
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 5 financial years
| 2023 | 2022 | 2021 | 2020 | 2019 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -163,2 k € | -17.2% | -139,3 k € | -951% | -13,3 k € | +94.2% | -229,1 k € | -173% | -84,1 k € |
| EBITDA | -281,9 k € | -16.1% | -242,8 k € | -99.9% | -121,5 k € | +53.9% | -263,2 k € | -84.5% | -142,7 k € |
| Operating result | -298,5 k € | -15.1% | -259,4 k € | -88.9% | -137,3 k € | +50.4% | -276,9 k € | -64.0% | -168,8 k € |
| Net result | -281,7 k € | +2.5% | -289 k € | -104% | -141,3 k € | +48.7% | -275,5 k € | -61.8% | -170,2 k € |
| Balance sheet | |||||||||
| Equity | 4,8 M € | +12.4% | 4,2 M € | +20.0% | 3,5 M € | +114% | 1,7 M € | -2.5% | 1,7 M € |
| Total assets | 5,2 M € | +4.0% | 5 M € | +21.1% | 4,1 M € | +116% | 1,9 M € | -1.2% | 1,9 M € |
| Cash | 218,6 k € | -65.4% | 632 k € | -47.8% | 1,2 M € | +30.0% | 931,8 k € | -41.9% | 1,6 M € |
| Debts | 380,8 k € | -46.4% | 710 k € | +27.7% | 556,1 k € | +125% | 247,3 k € | +9.5% | 225,8 k € |
Governance
Board of directors
Seen on filing of 31/12/2023 · 7 active · 17 ended
Active mandates
Dixon Graham
ActiveBLUEWAVE BIOTECHNOLOGY
ActiveActive
Active
Active
Active
Ended mandates
BLUEWAVE BIOTECHNOLOGY
EndedFinancials
Annual accounts
Full financial information
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Type of account | Abridged model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 10/08/2018 |
| Closing of the financial year | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 17 months |
| Filing date | 15/07/2024 | 30/06/2023 | 19/07/2022 | 16/07/2021 | 15/07/2020 |
| General meeting | 19/06/2024 | 21/06/2023 | 15/06/2022 | 16/06/2021 | 17/06/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
5 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2023 | 19/06/2024 | 15/07/2024 | French | |
| Micro model | 31/12/2022 | 21/06/2023 | 30/06/2023 | French | |
| Micro model | 31/12/2021 | 15/06/2022 | 19/07/2022 | French | |
| Micro model | 31/12/2020 | 16/06/2021 | 16/07/2021 | French | |
| Micro model | 31/12/2019 | 17/06/2020 | 15/07/2020 | French |
Valuation
Estimate
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2023 · 7 active · 17 ended
Active mandates
Dixon Graham
ActiveBLUEWAVE BIOTECHNOLOGY
ActiveActive
Active
Active
Active
Ended mandates
BLUEWAVE BIOTECHNOLOGY
EndedShareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
- Dissolution21/01/2025DISSOLUTION ET CLÔTURE IMMEDIATE DE LA LIQUIDATION (en
- Mandates21/05/2024Nomination d'un administrateur et du président du conseil d'administration
- Capital / shares04/05/2023STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Mandates06/10/2022DEMISSIONS, NOMINATIONS
- Capital / shares20/07/2022STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Other17/09/2021STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
- Capital / shares28/05/2021CAPITAL, ACTIONS
- Other18/11/2020STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2023Annual accounts 2023-281,7 k €↑
- 2022Annual accounts 2022-289 k €↓
- 2021Annual accounts 2021-141,3 k €↑
- 2020Annual accounts 2020-275,5 k €↓
- 2019Annual accounts 2019-170,2 k €